Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|11|6|731-745

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.11, Iss.6, 2004-03, pp. : 731-745

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

By  

Current Drug Targets, Vol. 11, Iss. 8, 2010-01 ,pp. : 1000-1017

Bentham Science Publishers

Access to resources Recommend Favorite

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

By Hartman George D   Fraley Mark E   Bilodeau Mark T  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 737-745

Informa Healthcare

Access to resources Recommend Favorite

Exploring QSARs of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitors by MLR, PLS and PC-ANN

By  

Current Pharmaceutical Design, Vol. 19, Iss. 12, 2013-01 ,pp. : 2237-2244

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

By  

Current Medicinal Chemistry, Vol. 23, Iss. 10, 2016-03 ,pp. : 1000-1040

Bentham Science Publishers

Access to resources Recommend Favorite

VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

By  

Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-01 ,pp. : 624-653

Bentham Science Publishers

Access to resources Recommend Favorite